Calidi Biotherapeutics Featured in NetworkNewsWire Spotlight on Genetic Medicines
Calidi Biotherapeutics' innovative approach to treating hard-to-treat cancers with engineered viruses is highlighted in a NetworkNewsWire editorial, showcasing its potential to transform cancer treatment and address autoimmune disorders.
Calidi Biotherapeutics Inc. (NYSE American: CLDI), a clinical-stage biotech company, has been featured in a NetworkNewsWire editorial titled 'Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers.' The article sheds light on Calidi's next-generation platform, which employs engineered viruses to deliver genetic therapies directly to tumors, offering new hope for patients with primary and metastatic cancers. While the company's initial focus is on oncology, it is also exploring applications in autoimmune disorders, indicating a broader therapeutic potential. This development is significant as it underscores Calidi's contribution to tackling the increasing global cancer burden and advancing innovative treatment options. For more details, visit https://ibn.fm/18sdm.